Abstract:OBJECTIVETo investigate the imunogenicity and protective efficacy of the divalent DNA vaccine encoding the antigens MPT83 and MPT64 of Mycobacterium tuberculosis.METHODSTwo genes of the M. tuberculosis, MPT83 and MPT64, were amplified and cloned into the vector pJW4303. The vector containing the fusion gene DNA-MM and pJW4303 blank vector were transfected into CO57 cells. The expression of DNA-MM in the supernatant was detected by Western blotting. Thirty-six C57BL/6 mice were divided into 3 equal groups to be injected subcutaneously with the vector containing the fusion gene DNA-MM, pJW4303 blank vector, or bacillus of Calmette-Guerin vaccine (BCG) once a week for 3 weeks. Twelve mice were used as non-immunized controls. Blood samples were collected from the mice before and after every immunization to detect the titer of antibody by ELISA. Three weeks after the 3rd immunization 3 mice from each were killed and their spleens were taken out. The splenocytes were cultured and stimulated by the recombinant antigen to detect the concentrations of interferon (IFN)-gamma and interleukin (IL)-4. Six weeks after the 3rd immunization M. tuberculosis of the line H37Rv was injected intravenously into the mice. Eight weeks later, the mice were killed and their lungs and spleens were taken out. The tissues were cultured to calculate the numbers of M. tuberculosis.RESULTSWestern blotting showed that the CO57 cells transfected with the vector containing the fusion gene expressed DNA-MM. ELISA showed that no antibody titer was detected before immunization in every group. The titer of MPT83 and MPT64 were increased to 1:200, 1:800, and 1:6400 3 weeks after the 1st, 2nd, and 3rd immunization respectively in the divalent group, increased to 1:800 3 weeks after the 3rd immunization in the BCG group, and remained 0 at any time points in the blank vector group. The IFN-gamma titer of the divalent group was 7520 pg/ml, significantly higher than that of the BCG group (6675.6 pg/ml, P < 0.05). The IL-4 concentration was basically the same and at the ng level in all groups. After challenge of H37Rv the bacterial loading in the lung was (2.21 +/- 0.032) x 10(5) in the divalent group, one thousandth of that in the blank vector group, and one tenth of that in the BCG group.CONCLUSIONThe divalent vaccine containing the antigens MPT83 and MPT64 effectively heightens the protective efficiency of vaccine against tuberculosis.

Combined DNA Vaccines Formulated in DDA Enhance Protective Immunity Against Tuberculosis.

DDA enhanced immunogenicity and protection of combined DNA vaccine against Mycobacterium tuberculosis

DDA is more efficacious than MPL as adjuvants that enhanced immunogenicity and protection of combined DNA vaccine against Mycobacteyium tuberculosisa

Combined DNA Vaccine Encapsulated in Microspheres Enhanced Protection Efficacy Against Mycobacterium Tuberculosis Infection of Mice

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

Protection of Mice with a Divalent Tuberculosis DNA Vaccine Encoding Antigens Ag85B and MPT64

Induction of an Immune-Protective T-Cell Repertoire with Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans

Combined Recombinant DNA Vaccine Results in Significant Protection Against Mycobacterium Tuberculosis

[Dimo-Thylidioctyl Ammonium Bromide-Bcg Polysaccharide Nucleic Acid Adjuvant Enhanced the Immunogenicity of a Mycobacterium Tuberculosis Subunit Vaccine].

Study on Immunogenicity and Protective Efficacy of Tetravalent Combination M-Tuberculosis Dna Vaccinea

Immunogenicity and Protective Efficacy Study Using Combination of Four Tuberculosis Dna Vaccines

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

A Combined DNA Vaccine Enhances Protective Immunity Against Mycobacterium Tuberculosis and Brucella Abortus in the Presence of an IL-12 Expression Vector

Coadministration of Interleukin 2 Plasmid Dna with Combined Dna Vaccines Significantly Enhances the Protective Efficacy Against Mycobacterium Tuberculosis

Ag85A DNA Vaccination Boosting Enhances BCG Primed-Mice Anti-Tuberculosis T Cell Responses

[Immunogenicity and Protection of Divalent DNA Vaccine Encoding Antigens MPT83 and MPT64 of Mycobacterium Tuberculosis].

Nanoparticle-based Adjuvant for Enhanced Protective Efficacy of DNA Vaccine Ag85A-ESAT-6-IL-21 Against Mycobacterium Tuberculosis Infection.

A Heterologous DNA Priming-Mycobacterium Bovis BCG Boosting Immunization Strategy Using Mycobacterial Hsp70, Hsp65, and Apa Antigens Improves Protection Against Tuberculosis in Mice.

Boosting BCG-primed Mice with Chimeric DNA Vaccine HG856A Induces Potent Multifunctional T Cell Responses and Enhanced Protection Against Mycobacterium Tuberculosis

Vaccination Against Tuberculosis by DNA Injection

The Combination of Mycobacterium Tuberculosis Fusion Proteins LT33 and LT28 Induced Strong Protective Immunity in Mice